SAFETY DATA SHEET
According to 13 December 2014, No:29204, “Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I”.

Mirtazapine Solid Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name : Mirtazapine Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company : MSD
Shotton Lane
NE23 3JU Cramlington NU - Great Britain
Telephone : 44 1 670 59 30 00
Telefax : 908-735-1496
E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification T.R. SEA No 28848
Reproductive toxicity, Category 2 : H361fd: Suspected of damaging fertility. Suspected of damaging the unborn child.
Specific target organ toxicity - repeated exposure, Category 2 : H373: May cause damage to organs through prolonged or repeated exposure.
Long-term (chronic) aquatic hazard, Category 3 : H412: Harmful to aquatic life with long lasting effects.

2.2 Label elements
Labelling T.R. SEA No 28848
Hazard pictograms : 
Signal word : Warning
Hazard statements : H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H373  May cause damage to organs through prolonged or repeated exposure.
H412  Harmful to aquatic life with long lasting effects.

Precautionary statements:

Prevention:
P201  Obtain special instructions before use.
P260  Do not breathe dust.
P273  Avoid release to the environment.
P280  Wear protective gloves/protective clothing/eye protection/face protection.

Response:
P308 + P313  IF exposed or concerned: Get medical advice/attention.

Storage:
P405  Store locked up.

Hazardous components which must be listed on the label:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine

2.3 Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine</td>
<td>85650-52-8</td>
<td>288-060-6</td>
<td></td>
<td></td>
<td>Acute Tox.4; H302 Repr.2; H361fd STOT RE1; H373 Aquatic Chronic2; H411</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures
General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Mirtazapine Solid Formulation

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.

Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-
Mirtazapine Solid Formulation

5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions

Environmental precautions: Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
SAFETY DATA SHEET
According to 13 December 2014, No:29204, "Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I".

Mirtazapine Solid Formulation

**6.4 Reference to other sections**
See sections: 7, 8, 11, 12 and 13.

**SECTION 7: Handling and storage**

7.1 **Precautions for safe handling**

**Technical measures**: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

**Local/Total ventilation**: Use only with adequate ventilation.

**Advice on safe handling**:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

**Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 **Conditions for safe storage, including any incompatibilities**

**Requirements for storage areas and containers**: Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.

**Advice on common storage**:
- Do not store with the following product types:
  - Strong oxidizing agents

7.3 **Specific end use(s)**

**Specific use(s)**: No data available

**SECTION 8: Exposure controls/personal protection**

8.1 **Control parameters**

**Occupational Exposure Limits**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>(+/-)-1,2,3,4,10,14b-Hexahydro-2-</td>
<td>85650-52-8</td>
<td>TWA</td>
<td>25 µg/m3</td>
<td>Internal</td>
</tr>
</tbody>
</table>
Mirtazapine Solid Formulation

8.2 Exposure controls

Engineering measures
Ensure adequate ventilation, especially in confined areas.
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Eye protection : Wear the following personal protective equipment:
Safety goggles
Equipment should conform to TS EN 166

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : powder
Colour : No data available
Odour : No data available
Odour Threshold : No data available
pH : No data available
Mirtazapine Solid Formulation

Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
Density: No data available
Solubility(ies)
Water solubility: No data available
Partition coefficient: n-octanol/water: No data available
Auto-ignition temperature: No data available
Decomposition temperature: No data available
Viscosity
Viscosity, dynamic: No data available
Viscosity, kinematic: No data available
Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.

9.2 Other information
Flammability (liquids): No data available
Molecular weight: No data available
Particle size: No data available
SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Acute oral toxicity: LD50 (Rat): 320 - 490 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.
Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Test system: Chinese hamster lung cells
  Result: negative
- Test Type: unscheduled DNA synthesis assay
  Test system: mammalian cells
  Result: negative
- Test Type: sister chromatid exchange assay
  Test system: mammalian cells
  Result: negative

Genotoxicity in vivo:
- Test Type: Micronucleus test
  Species: Rat
  Cell type: Bone marrow
  Application Route: Oral
  Result: negative

Carcinogenicity
Not classified based on available information.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species: Mouse
Application Route: Oral
Exposure time: 18 month(s)
LOAEL: 200 mg/kg body weight
Result: equivocal
Target Organs: Liver

Species: Rat
Application Route: Oral
Exposure time: 2 Years
LOAEL: 20 mg/kg body weight
Result: equivocal
# Mirtazapine Solid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3</td>
<td>09/13/2019</td>
<td>2805574-00005</td>
<td>24.04.2019</td>
<td>18.05.2018</td>
</tr>
</tbody>
</table>

**Target Organs**: Liver, Thyroid

**Reproductive toxicity**
Suspected of damaging fertility. Suspected of damaging the unborn child.

**Components**:

\((+/-)1,2,3,4,10,14b\text{-Hexahydro-2-methylpyrazino\([2,1-a]\text{-pyrido\([2,3-c\text{-c]}\text{]benzazepine}\):}

**Effects on fertility**
- **Test Type**: Fertility/early embryonic development
- **Species**: Rat
- **Application Route**: Oral
- **Fertility**: LOAEL: 15 mg/kg body weight
- **Symptoms**: Effect on estrous cycle, increase of early resorptions
- **Result**: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.

**Effects on foetal development**
- **Test Type**: Development
- **Species**: Rat
- **Application Route**: Oral
- **Developmental Toxicity**: LOAEL: 100 mg/kg body weight
- **Result**: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects

- **Test Type**: Development
- **Species**: Rabbit
- **Application Route**: Oral
- **Developmental Toxicity**: NOAEL: 40 mg/kg body weight
- **Result**: No adverse effects, No teratogenic effects

**Reproductive toxicity - Assessment**: Some evidence of adverse effects on sexual function and fertility, based on animal experiments.; Some evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**
Not classified based on available information.

**STOT - repeated exposure**
May cause damage to organs through prolonged or repeated exposure.

**Components**:

\((+/-)1,2,3,4,10,14b\text{-Hexahydro-2-methylpyrazino\([2,1-a]\text{-pyrido\([2,3-c\text{-c]}\text{]benzazepine}\):}

**Exposure routes**
- Ingestion

**Target Organs**
- Nervous system

**Assessment**
- May cause damage to organs through prolonged or repeated exposure.
SAFETY DATA SHEET
According to 13 December 2014, No:29204, “Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I”.

Mirtazapine Solid Formulation

Repeated dose toxicity

Components:

\((\pm)\text{-}1,2,3,4,10,14b\text{-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:}\)

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>120 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Nervous system</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>15 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>52 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>20 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Nervous system, Testis</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors</td>
</tr>
</tbody>
</table>

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

\((\pm)\text{-}1,2,3,4,10,14b\text{-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:}\)

Ingestion: Symptoms: Drowsiness, constipation, dry mouth, asthenia, Dizziness, Disorientation

SECTION 12: Ecological information

12.1 Toxicity

Components:

\((\pm)\text{-}1,2,3,4,10,14b\text{-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:}\)

Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): 6,92 mg/l Exposure time: 96 h Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 19,5 mg/l Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 5,7 mg/l
Mirtazapine Solid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3</td>
<td>09/13/2019</td>
<td>2805574-00005</td>
<td>24.04.2019</td>
<td>18.05.2018</td>
</tr>
</tbody>
</table>

Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms:
EC50 (Natural microorganism): > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity):
NOEC: 3.6 mg/l
Exposure time: 31 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC: 0.32 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential

Components:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Bioaccumulation: Species: Oncorhynchus mykiss (rainbow trout)
Bioconcentration factor (BCF): 334
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 2,78

12.4 Mobility in soil

Components:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Distribution among environmental compartments: log Koc: 4,48

12.5 Results of PBT and vPvB assessment
Not relevant
Mirtazapine Solid Formulation

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
KKDIK (30105 (Bis)) - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex 17) : Not applicable

Other regulations:
According to 13 December 2014, No:29204, “Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I”. Regulation on Classification, Labelling and Packaging of Substances and Mixtures. Dated 11
Mirtazapine Solid Formulation


The components of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-statements

- H302: Harmful if swallowed.
- H361fd: Suspected of damaging fertility. Suspected of damaging the unborn child.
- H373: May cause damage to organs through prolonged or repeated exposure if swallowed.
- H411: Toxic to aquatic life with long lasting effects.

The Turkish SDS has been prepared according to the Regulation on Safety Data Sheets for Hazardous Substances and Mixtures No. 29204.

Full text of other abbreviations

- Acute Tox.: Acute toxicity
- Aquatic Chronic: Long-term (chronic) aquatic hazard
- Repr.: Reproductive toxicity
- STOT RE: Specific target organ toxicity - repeated exposure
Mirtazapine Solid Formulation

Version: 2.3  Revision Date: 09/13/2019  SDS Number: 2805574-00005  Date of last issue: 24.04.2019  Date of first issue: 18.05.2018

Further information

Classification of the mixture:
- Repr. 2: H361fd  Calculation method
- STOT RE 2: H373  Calculation method
- Aquatic Chronic 3: H412  Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

TR / EN